Integra LifeSciences Introduces Allograft Cancellous Sponge
February 07 2011 - 6:00AM
Integra LifeSciences Holdings Corp (Nasdaq:IART) announced today
the launch of Integra™ Allograft Cancellous Sponge, a compressible
bone graft composed of 100% cancellous bone. The sponge-like
handling characteristics of Integra™ Allograft Cancellous Sponge
allow it to absorb fluids like saline, blood or bone marrow
aspirate. After rehydration, Integra™ Allograft Cancellous
Sponge can be compressed to half its original size, and expands
back to conform to a variety of spaces and defects, for maximum
surgical flexibility.
"The unique handling characteristics and biocompatibility of
Integra™ Allograft Cancellous Sponge make it an ideal addition to
Integra's portfolio of allografts and orthobiologics, and provide
another flexible solution for improving patient care," said Bill
Weber, Vice President of Integra OrthoBiologics.
Surgeons frequently remove bone from the spine, extremities and
pelvis that has been damaged by trauma, degenerative conditions and
aging. Bone grafts are generally needed to fill in these
defects and aid the body in regenerating new bone. Bone grafts
provide a foundation or scaffold for the patient's body to grow new
bone, and encourage new bone production and bone fusion.
Surgeons have historically obtained healthy bone graft material
from the patient's own body, often from the iliac crest of the
pelvis. Sourcing bone graft material in this manner requires
additional surgery that may cause post-operative pain, and there is
also a limit on how much of the patient's bone may be removed from
the donor site.
Integra™ Allograft Cancellous Sponge offers a unique alternative
for use as a bone graft in spinal fusion or general orthopedic
surgeries. It may reduce the need to harvest the patient's own
bone, sparing the patient additional surgery and limiting the risk
of any associated complications.
The U.S. market size for bone graft substitutes in orthopedic
spinal procedures is estimated at $560 million, excluding growth
factors, stem cell therapies, and machined bone. In 2010, an
estimated 1,050,000 orthopedic procedures were performed in the
United States, including over 450,000 spinal fusions. Additional
applications are found in orthopedic trauma and reconstructive
procedures.
The Integra distributor network sells Integra™ Allograft
Cancellous Sponge in the United States. Integra's extensive line of
orthobiologic products allows the distributor network to provide a
complete range of bone graft substitutes to orthopedic surgeons and
neurosurgeons.
Integra LifeSciences, a world leader in medical devices, is
dedicated to limiting uncertainty for surgeons, so they can
concentrate on providing the best patient care. Integra
offers innovative solutions in orthopedics, neurosurgery, spine,
reconstructive and general surgery. For more information, please
visit www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include, but are not limited
to, statements concerning the products and services provided by
Integra. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from predicted or expected results. Among other things, the
willingness of surgical professionals to use Integra™ Allograft
Cancellous Sponge may affect the prospects for its use in surgical
procedures. In addition, the economic, competitive,
governmental, technological and other factors, identified under the
heading "Risk Factors" included in Item IA of Integra's Annual
Report on Form 10-K for the year ended December 31, 2009 and
information contained in subsequent filings with the Securities and
Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director of Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From May 2024 to Jun 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Jun 2023 to Jun 2024